Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCR-TILES-ESCC
NCT07678580Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jul 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tangdu Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07678580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678580.